The purpose of this study was to compare the effect of CML treatment on theexpression of key mediators in the RAGE pathway in the blood cells of patients withnephropathy and those with T2DM. The gene discussed is AGER; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.